Exploratory, Placebo-controlled Study on the Effects of Bifidobacterium Breve in Children With Celiac Disease
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 66
- 主要终点
- Serum TNF-alpha decrease after Bifidobacterium breve daily consumption in children with celiac disease
研究概览
简要总结
Celiac disease (CD) is an immune-mediated systemic disease that is elicited by consumption of gluten and related prolamines in genetically susceptible individuals. Not only genetic but also environmental factors play an important role in CD pathogenesis. CD patients have imbalance in the gut microbiota, they have reduced number of Bididobacterium species in feces and biopsies.
Up till now, only effective treatment for CD is life long adherence to gluten free diet. If gluten free diet is not strict that leads over the years to complications of disease, such as autoimmune diseases, psychiatric diseases, osteoporosis etc. That may be caused by continuous recirculation of activated immune cells between the inflamed organ and the periphery. To avoid complications of disease in long term the investigators want to test specific probiotic bacteria from Bifidobacteria genus, that has has been in vitro studies recognized as anti-inflammatory.
Hypothesis
- Children with celiac disease on gluten free diet have a higher level of pro-inflammatory cytokine (TNF-alpha) and anti-inflammatory cytokine (IL-10) in comparison with healthy controls.
- 3 months after daily probiotic consumption TNF-alpha level decrease and IL-10 level increase.
In the investigators research will be selected 70 children, age from 2 to 18 years, divided in different groups:
- Group: 25 children with celiac disease on GFD for at least 3 months and will receive probiotic for 3 months.
- Group: 25 children with celiac disease on GFD for at least 3 months and will receive placebo for 3 months.
- Group: 20 healthy children
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 1 Year 至 18 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •celiac disease on gluten free diet
排除标准
- •acute or chronic diseases,
- •permanent use of medication and
- •ingestion of antibiotics at least one month prior to study
研究组 & 干预措施
Bifidobacterium breve
Bifidobacterium breve BR03 and B632 powder containing 10/9 CFU daily dosage in a period of 3 months
干预措施: Bifidobacterium breve (Drug)
Placebo
Placebo in the same powder packages as Bifidobacterium breve
干预措施: Placebo (for Bifidobacterium breve) (Drug)
结局指标
主要结局
Serum TNF-alpha decrease after Bifidobacterium breve daily consumption in children with celiac disease
时间窗: 3 months
次要结局
未报告次要终点
研究者
Martina Klemenak
medical doctor, resident at Pediatric department
University Medical Centre Maribor
